Associations between fluid biomarkers and PET imaging ([ 11 C]UCB-J) of synaptic pathology in Alzheimer’s disease
Authors:
Preprint
Abstract
INTRODUCTION: Positron Emission Tomography (PET) imaging with ligands for synaptic vesicle glycoprotein 2A (SV2A) has emerged as a promising methodology for measuring synaptic density in Alzheimer’s disease (AD). We investigate the relationship between SV2A PET and CSF synaptic protein changes of AD patients. METHOD: Twenty-one participants with early AD and 7 cognitively normal (CN) individuals underwent [ 11 C]UCB-J PET. We used mass spectrometry to measure a panel of synaptic proteins in CSF. RESULTS: In the AD group, higher levels of syntaxin-7 and PEBP-1 were associated with lower global synaptic density. In the total sample, lower global synaptic density was associated with higher levels of AP2B1, neurogranin, γ-synuclein, GDI-1, PEBP-1, syntaxin-1B, and syntaxin-7 but not with the levels of the neuronal pentraxins or 14-3-3 zeta/delta. CONCLUSION: Reductions of synaptic density found in AD compared to CN participants using [ 11 C]UCB-J PET were observed to be associated with CSF biomarker levels of synaptic proteins.Keywords
All Related Versions
- Published version: Alzheimer's & Dementia, 21 (7), e70403.
This publication has 36 references indexed in Scilit:
- Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disordersAlzheimer's & Dementia, 2022
- Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's diseaseAlzheimer's & Dementia, 2021
- Reduced Synaptic Density in Patients with Lewy Body Dementia: An [11C]UCB‐J PET Imaging StudyMovement Disorders, 2021
- Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's diseaseAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021
- Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuumAlzheimer's & Dementia, 2020
- In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PETAlzheimer's & Dementia, 2020
- Synaptic Changes in Parkinson Disease Assessed with in vivo ImagingAnnals of Neurology, 2020
- Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic ImagingJAMA Neurology, 2018
- Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusingElectrophoresis, 1999
- Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairmentAnnals of Neurology, 1991